NEXGEL, INC.

NXGL Nasdaq CIK: 0001468929

Company Information

Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 2150 CABOT BLVD WEST,, LANGHORNE, PA, 19047
Mailing Address 2150 CABOT BLVD WEST,, LANGHORNE, PA, 19047
Phone 215 702-8550
Fiscal Year End 1231
EIN 264042544

Financial Overview

FY2025

-$3.28M
Net Income
$5.57M
Total Liabilities
$-0.38
EPS

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 31, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) March 12, 2026 View on SEC
8-K Current report of material events March 10, 2026 View on SEC
8-K Current report of material events February 11, 2026 View on SEC
424B5 Prospectus supplement February 10, 2026 View on SEC
8-K Current report of material events January 30, 2026 View on SEC
8-K Current report of material events January 7, 2026 View on SEC
4 Insider stock transaction report December 29, 2025 View on SEC
8-K Current report of material events December 11, 2025 View on SEC
8-K Current report of material events November 24, 2025 View on SEC

Annual Reports

10-K March 31, 2026
  • High-capacity facility operating at only 15-20% utilization, allowing for massive production scaling without new capital expenditure.
  • Strategic shift toward high-margin medical device patent licensing to major industry players like 3M.
View Analysis

Material Events

8-K Strategy Change December 11, 2025
High Impact
  • NEXGEL, INC. is spinning off a portion of its drug delivery program into a new, separate company called NexGelRx, Inc.
  • NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx (for the first $8 million of capital raised by NexGelRx).
View Analysis

Insider Trading

SELL 1 insiders 2 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 3841)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.